top of page
Insights for Life Sciences Talent Leaders
Strategic guidance on life sciences executive recruitment and human capital for search partners, biotech innovators, and scale-up HR leaders. I also share occasional personal reflections on the industry.


The True Cost of a Poor Senior Hire in Life Sciences
A poor senior hire in Life Sciences can cost far more than recruitment fees and replacement expenses. Delayed milestones, lost productivity, weakened trust, and reduced willingness to speak up can all affect organizational performance. This article explores the financial and cultural impact—and how to reduce the risk before making a pivotal appointment.
sharonshieldsconsu
6 days ago4 min read


Q3 Pharma Earnings: Portfolio Renewal, Therapeutic-Area Concentration, and the Shift to Innovation-Led Growth
Q3 pharmaceutical results highlight a sector moving beyond pandemic-driven revenues toward innovation-led growth. Demand for obesity and specialty medicines is driving strong performance for companies with differentiated products, while mature and COVID-related portfolios continue to face pressure. Acquisitions and portfolio renewal are reshaping growth prospects, even as one-off costs can obscure underlying performance.
For life sciences leaders, this shift has implications
sharonshieldsconsu
Nov 95 min read


Patient Advocacy: A Strategic Partner in Rare Disease Commercialisation
Rare Disease as a Strategic Growth Engine Rare disease is no longer just a scientific or regulatory story — it is a commercial one. But in rare disease, “the market” is not an abstract concept. It is a small, tightly connected ecosystem of patients, caregivers, advocates, clinicians, and payers who all know each other — and who expect to be true partners. Speaking to many global commercial leader over the last few weeks Patient advocacy has been a re-occurring theme. For glob
sharonshieldsconsu
Aug 225 min read


Rare Disease Is No Longer a Niche — It's a Strategic Commercial Priority
Rare disease is no longer a niche topic — it has become a strategic priority
for global commercial leaders and asset teams.
As regulatory momentum builds and companies refine how they identify patients,
generate evidence, and shape markets, rare disease is increasingly where scientific
innovation and commercial differentiation meet.
sharonshieldsconsu
Aug 164 min read
bottom of page